TKPHF - Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
2025-01-09 15:56:43 ET
Summary
- Denali Therapeutics Inc.'s DNL343 failed to meet the primary endpoint in the phase 2/3 HEALY ALS trial, but potential biomarker analyses in 2025 may offer a path forward.
- Despite the trial setback in ALS, Denali's stock remains stable due to continued pre-specified analyses expected in late 2025.
- BLA filing of tividenofusp alfa for the treatment of patients with MPS II remains on track under the Accelerated Approval Pathway Program in early 2025.
- Financially, Denali has $1.28 billion in cash but may need additional funding in 2025, posing a risk of shareholder dilution.
Denali Therapeutics Inc. ( DNLI ) recently reported results from its phase 2/3 HEALEY ALS Platform Trial using DNL343 for the treatment of patients with Amyotrophic Lateral Sclerosis [ALS]. It was noted that the primary endpoint of the study, which was to see a change in slowing of disease severity over time measured by ALS Functional Rating Scale-Revised [ALSFRS-R] & survival through week 24, was not met with statistical significance. While this was disappointing, the stock hasn't really traded that much lower since. Matter of fact, the stock is actually stable at around the $21.50 per-share price. There are two reasons why I believe this is the case and why value remains despite this failure....
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains